首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Extracellular vesicles as drug delivery systems: Lessons from the liposome field
【24h】

Extracellular vesicles as drug delivery systems: Lessons from the liposome field

机译:细胞外囊泡作为药物输送系统:脂质体领域的经验教训

获取原文
获取原文并翻译 | 示例
           

摘要

Extracellular vesicles (EVs) are membrane-derived particles surrounded by a (phospho)lipid bilayer that are released by cells in the human body. In addition to direct cell-to-cell contact and the secretion of soluble factors, EVs function as anothermechanismof intercellular communication. These vesicles are able to efficiently deliver their parental cell-derived molecular cargo to recipient cells, which can result in structural changes at an RNA, protein, or even phenotypic level. For this reason, EVs have recently gained much interest for drug delivery purposes. In contrast to these 'natural delivery systems', synthetic (phospho)lipid vesicles, or liposomes, have been employed as drug carriers for decades, resulting in several approved liposomal nanomedicines used in the clinic. This review discusses the similarities and differences between EVs and liposomes with the focus on features that are relevant for drug delivery purposes such as circulation time, biodistribution, cellular interactions and cargo loading. By applying beneficial features of EVs to liposomes and vice versa, improved drug carriers can be developed which will advance the field of nanomedicines and ultimately improve patient outcomes. While the application of EVs for therapeutic drug delivery is still in its infancy, issues regarding the understanding of EV biogenesis, largescale production and in vivo interactions need to be addressed in order to develop successful and cost-effective EV-based drug delivery systems.
机译:细胞外囊泡(EVs)是被(磷脂)脂质双层包围的膜衍生颗粒,被人体细胞释放。除了直接的细胞间接触和可溶性因子的分泌外,电动汽车还作为细胞间通讯的另一种机制。这些囊泡能够将其亲本细胞衍生的分子货物有效地递送至受体细胞,这可能导致RNA,蛋白质甚至表型水平的结构改变。由于这个原因,电动汽车最近在药物输送方面引起了很多兴趣。与这些“天然递送系统”相反,合成(磷脂)脂质囊泡或脂质体已被用作药物载体数十年,从而产生了几种在临床上使用的批准的脂质体纳米药物。这篇评论讨论了电动汽车和脂质体之间的异同,重点是与药物传递目的相关的特征,例如循环时间,生物分布,细胞相互作用和货物装载。通过将电动汽车的有益特性应用于脂质体,反之亦然,可以开发出改进的药物载体,这将推动纳米医学领域的发展并最终改善患者的治疗效果。虽然电动汽车在治疗药物输送中的应用仍处于起步阶段,但为了开发成功且具有成本效益的基于电动汽车的药物输送系统,需要解决与对电动汽车生物发生,大规模生产和体内相互作用的理解有关的问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号